How we treat febrile neutropenia in patients receiving cancer chemotherapy

Journal of Oncology Practice

Volumn 6, Issue 3, 2010, Pages 149-152

  Lyman, Gary H ^a   Rolston, Kenneth V I ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; MYELOID GROWTH FACTOR; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATE; BLOOD CELL COUNT; BLOOD CULTURE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL EVALUATION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPUTER ASSISTED TOMOGRAPHY; EMERGENCY CARE; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HIGH RISK PATIENT; HOSPITAL CARE; HUMAN; HYPOTENSION; INFECTION COMPLICATION; KLEBSIELLA; LABORATORY TEST; LIVER FUNCTION TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MORBIDITY; MYCOSIS; NEUTROPENIC ENTEROCOLITIS; NEUTROPHIL COUNT; OUTPATIENT CARE; PENICILLIN RESISTANCE; PERIPHERAL VEIN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; SHOCK; STAPHYLOCOCCUS AUREUS; STEM CELL TRANSPLANTATION; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS VIRIDANS INFECTION; THORAX RADIOGRAPHY; TREATMENT INDICATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 77956606633     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.091092     Document Type: Review

References (40)

1. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002
2. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
3. Paul M, Yahav D, Fraser A, et al: Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57:176-189, 2006 (Pubitemid 43160156)
4. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006 (Pubitemid 43673249)
5. González-Barca E, Fernández-Sevilla A, Carratalá J, et al: Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 18:539-544, 1999 (Pubitemid 29531221)
6. Malik I, Hussain M, Yousuf H: Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: Need for better strategies. J Infect 42:120-125, 2001 (Pubitemid 32631813)
7. Darmon M, Azoulay E, Alberti C, et al: Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775-1780, 2002 (Pubitemid 35435480)
8. Carratalà J, Rosón B, Fernández-Sevilla A, et al: Bacteremic pneumonia in neutropenic patients with cancer: Causes, empirical antibiotic therapy, and outcome. Arch Intern Med 158:868-872, 1998 (Pubitemid 28183641)
9. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003
10. Schiel X, Hebart H, Kern WV, et al: Sepsis in neutropenia: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82:S158-S166, 2003 (suppl 2)
11. Wisplinghoff H, Seifert H, Wenzel RP, et al: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103-1110, 2003 (Pubitemid 36553108)
12. Elting LS, Rubenstein EB, Rolston KV, et al: Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247-259, 1997
13. Lyman GH, Morrison VA, Dale DC, et al: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069-2076, 2003
14. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21:4524-4531, 2003
15. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004 (Pubitemid 41185151)
16. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
17. Crawford J, Armitage J, Balducci L, et al: Myeloid growth factors. J Natl Compr Canc Netw 7:64-83, 2009
18. Caillot D, Couaillier JF, Bernard A, et al: Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19:253-259, 2001
19. Yadegarynia D, Tarrand J, Raad I, et al: Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 37:1144-1145, 2003
20. Rolston KV, Yadegarynia D, Kontoyiannis DP, et al: The spectrum of Grampositive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis 10:223-230, 2006
21. Safdar A, Rolston KV: Immunocompromised hosts: Stenotrophomonas maltophilia - Changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45:1602-1609, 2007
22. Rolston KV, Bodey GP, Safdar A: Polymicrobial infection in patients with cancer: An underappreciated and underreported entity. Clin Infect Dis 45:228-233, 2007
23. Klastersky J, Ameye L, Maertens J, et al: Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51-S59, 2007 (suppl 1)
24. Rolston KV: Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40:S246-S252, 2005 (suppl 4)
25. Han XY, Kamana M, Rolston KV: Viridans streptococci isolated by culture from blood of cancer patients: Clinical and microbiologic analysis of 50 cases. J Clin Microbiol 44:160-165, 2006
26. Kumashi P, Girgawy E, Tarrand JJ, et al: Streptococcus pneumoniae bacteremia in patients with cancer: Disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 84:303-312, 2005
27. Cornely OA, Maertens J, Winston DJ, et al: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348-359, 2007
28. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000
29. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
30. Kern WV: Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 42:533-540, 2006
31. Rolston KVI, Frisbee-Hume SE, Patel S, et al: Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18:89-94, 2010
32. Klastersky J, Paesmans M, Georgala A, et al: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134, 2006
33. Sung L, Nathan PC, Lange B, et al: Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 22:3350-3356, 2004
34. Clark OA, Lyman GH, Castro AA, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005
35. Dellit TH, Owens RC, McGowan JE Jr, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159-177, 2007
36. Moellering RC Jr, Graybill JR, McGowan JE Jr, et al: Antimicrobial resistance prevention initiative: An update - Proceedings of an expert panel on resistance. Am J Med 120:S4-S25, 2007; quiz S26-S28
37. Bucaneve G, Micozzi A, Menichetti F, et al: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977-987, 2005
38. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
39. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25:3158-3167, 2007
40. Lyman GH, Kleiner JM: Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 5:217-228, 2007